Search a title or topic

Over 20 million podcasts, powered by 

Player FM logo
Artwork

Content provided by Sano Genetics. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Sano Genetics or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://podcastplayer.com/legal.
Player FM - Podcast App
Go offline with the Player FM app!

EP 212: A hub-and-spoke model for accelerating rare disease drug development with Ananth Sridhar and Sun-Gou Ji of BridgeBio

46:05
 
Share
 

Manage episode 517985624 series 2631947
Content provided by Sano Genetics. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Sano Genetics or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://podcastplayer.com/legal.

Summary:

This week on The Genetics Podcast, Patrick is joined by BridgeBio’s Ananth Sridhar, Chief Operating Officer of Cardiorenal Programs, and Sun-Gou Ji, Vice President of Computational Genomics. They discuss the hub-and-spoke model for de-risking and accelerating rare disease drug development, the role of human genetics in target discovery, lessons from their autosomal dominant hypocalcemia type 1 (ADH1) program, and how portfolio design and predictive genomics are shaping the future of precision medicine.

Show Notes:

0:00 Intro to The Genetics Podcast

00:59 Welcome to Ananth & Sun-Gou

01:57 How BridgeBio’s hub-and-spoke model de-risks and accelerates rare disease drug development

06:45 How programs move from the hub to the spokes in target discovery and development

09:10 Translating a target into a therapy for autosomal dominant hypocalcemia type 1 (ADH1)

12:28 Challenges in ADH1 drug development and using population genetics to identify patients with gain-of-function variants

18:08 Under-diagnosis and incomplete penetrance in rare disease and quantifying genetic versus phenotypic prevalence

20:52 Balancing first-in-class innovation with risk management in rare disease drug development

24:24 Evaluating rare disease programs using risk-adjusted net present value (NPV) instead of peak sales

27:20 Key factors that can make rare disease programs faster and cheaper to develop, and why modality agnosticism is important

32:00 Sun-Gou’s experience in computational genetics and building data-driven infrastructure for discovery

36:44 Ananth’s lessons from Regeneron and applying patient-centered principles to rare disease drug development

39:00 Sun-Gou on the power of newborn sequencing and personal lessons from early diagnosis

43:36 Ananth’s views on making predictive medicine more personal and human-centered

44:51 Closing remarks

Find out more

Please consider rating and reviewing us on your chosen podcast listening platform!

https://drive.google.com/file/d/1Bp2_wVNSzntTs_zuoizU8bX1dvao4jfj/view?usp=share_link

  continue reading

215 episodes

Artwork
iconShare
 
Manage episode 517985624 series 2631947
Content provided by Sano Genetics. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Sano Genetics or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://podcastplayer.com/legal.

Summary:

This week on The Genetics Podcast, Patrick is joined by BridgeBio’s Ananth Sridhar, Chief Operating Officer of Cardiorenal Programs, and Sun-Gou Ji, Vice President of Computational Genomics. They discuss the hub-and-spoke model for de-risking and accelerating rare disease drug development, the role of human genetics in target discovery, lessons from their autosomal dominant hypocalcemia type 1 (ADH1) program, and how portfolio design and predictive genomics are shaping the future of precision medicine.

Show Notes:

0:00 Intro to The Genetics Podcast

00:59 Welcome to Ananth & Sun-Gou

01:57 How BridgeBio’s hub-and-spoke model de-risks and accelerates rare disease drug development

06:45 How programs move from the hub to the spokes in target discovery and development

09:10 Translating a target into a therapy for autosomal dominant hypocalcemia type 1 (ADH1)

12:28 Challenges in ADH1 drug development and using population genetics to identify patients with gain-of-function variants

18:08 Under-diagnosis and incomplete penetrance in rare disease and quantifying genetic versus phenotypic prevalence

20:52 Balancing first-in-class innovation with risk management in rare disease drug development

24:24 Evaluating rare disease programs using risk-adjusted net present value (NPV) instead of peak sales

27:20 Key factors that can make rare disease programs faster and cheaper to develop, and why modality agnosticism is important

32:00 Sun-Gou’s experience in computational genetics and building data-driven infrastructure for discovery

36:44 Ananth’s lessons from Regeneron and applying patient-centered principles to rare disease drug development

39:00 Sun-Gou on the power of newborn sequencing and personal lessons from early diagnosis

43:36 Ananth’s views on making predictive medicine more personal and human-centered

44:51 Closing remarks

Find out more

Please consider rating and reviewing us on your chosen podcast listening platform!

https://drive.google.com/file/d/1Bp2_wVNSzntTs_zuoizU8bX1dvao4jfj/view?usp=share_link

  continue reading

215 episodes

All episodes

×
 
Loading …

Welcome to Player FM!

Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.

 

Copyright 2025 | Privacy Policy | Terms of Service | | Copyright
Listen to this show while you explore
Play